Periostin remains an exploratory biomarker in the context of IPF, primarily due to the limited number of large, multicenter, and prospective validation studies compared to more established biomarkers, such as MMP-7, KL-6, or SP-D. This evidence concerns the gene SFTPD and idiopathic interstitial pneumonia.